SCHEMBL420932

SCHEMBL420932

COC(=O)c1cc(Cl)ccc1NC(=O)Cc1ccc(-c2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
POLB P06746 1/20 0.57
GAA P10253 2/20 0.56
KDM4E B2RXH2 2/20 0.56
ACLY P53396 1/20 0.53
SERPINE1 P05121 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
HCAR2 Q8TDS4 1/20 0.49
ALDH1A1 P00352 4/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NPC1 O15118 1/20 0.48
HPGD P15428 1/20 0.48
RIOK2 Q9BVS4 1/20 0.48
MAPK1 P28482 1/20 0.48
SLC6A4 P31645 1/20 0.48
SLC6A3 Q01959 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL417913 0.88 SERPINE1 (0.66) MEN1KMT2APOLBGAAKDM4E
SCHEMBL21819805 0.85 POLB (0.54) MEN1KMT2APOLBGAAKDM4E
SCHEMBL420221 0.84 ALDH1A1 (0.68) GAASERPINE1L3MBTL1HCAR2ALDH1A1
SCHEMBL8037966 0.81 MEN1 (0.50) MEN1KMT2APOLBGAAKDM4E
SCHEMBL25279829 0.80 POLB (0.56) MEN1KMT2APOLBKDM4EALDH1A1
SCHEMBL30232769 0.80 POLB (0.56) MEN1KMT2APOLBKDM4EALDH1A1
SCHEMBL22022864 0.80 ACLY (0.75) MEN1KMT2AKDM4EACLYL3MBTL1
SCHEMBL22000651 0.80 ACLY (0.78) MEN1KMT2APOLBKDM4EACLY
SCHEMBL416730 0.80 SERPINE1 (0.66) MEN1KMT2APOLBGAAKDM4E
SCHEMBL418556 0.79 SERPINE1 (0.61) MEN1KMT2APOLBGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 MEN1 844/4885KMT2A 4433/4885POLB 2730/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 MEN1 844/4885KMT2A 4433/4885POLB 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.